GenSight Biologics Company
We are an innovative clinical-stage gene therapy company currently focused on discovering, developing and commercializing novel therapies for patients with severe retinal neurodegenerative diseases. In the longer term, we hope to find solutions for patients faced with neurodegenerative diseases more generally.
Investors
.jpg)
Founded Date:
2012
Funding Status:
IPO
Technology:
Neurological Disorders
Industry:
Energetic Process
Headquarters:
France
Estimated Revenue:
$1M to $10M